^ ab
Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (February 2004). “Molecular characterization of a phospholipase D generating anandamide and its congeners”. J. Biol. Chem.279 (7): 5298–305. doi:10.1074/jbc.M306642200. PMID14634025.
^Di Marzo (1998). “'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance.”. Biochimica et Biophysica Acta1392 (2–3): 153–75. doi:10.1016/s0005-2760(98)00042-3. PMID9630590.
^Di Marzo; De Petrocellis, L; Fezza, F; Ligresti, A; Bisogno, T (2002). “Anandamide receptors”. Prostaglandins, leukotrienes, and essential fatty acids66 (2–3): 377–91. doi:10.1054/plef.2001.0349. PMID12052051.
^Lambert; Vandevoorde, S; Jonsson, KO; Fowler, CJ (2002). “The palmitoylethanolamide family: a new class of anti-inflammatory agents?”. Current medicinal chemistry9 (6): 663–74. doi:10.2174/0929867023370707. PMID11945130.
^Rodríguez De Fonseca; Navarro, M; Gómez, R; Escuredo, L; Nava, F; Fu, J; Murillo-Rodríguez, E; Giuffrida, A et al. (2001). “An anorexic lipid mediator regulated by feeding”. Nature414 (6860): 209–12. doi:10.1038/35102582. PMID11700558.